1. Elomaa I, Blomqvist C, Rissanen P: Aminoglutethimide as second line therapy in advanced breast cancer. Breast Cancer Res Treat 7 (suppl): 51–54, 1986
2. Canney PA, Priestman TJ, Griffiths T, Latief TN, Mould JJ, Spooner D: Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma. J Natl Cancer Inst 80: 1147–1151, 1988
3. Garcia-Giralt E, Hurteloup P, Chollet P, Bastit P, Chevalier B, Delozier T, Le Floch O, Mercier M, Monicuquet P, Metz R, Delgado M, Weber B, Serin D, Daban A, Pourny C, Olivier JP, Roche H, Van V, Pouillart P: Breast cancer first line hormonotherapy: a multicenter randomized trial comparing TAM with MAP and their sequential administration. Proc ASCO 1987, p 61
4. Congdon J, Green S, O'Sullivan J, Hynes H, Belt R, Gail K, Zidar B, Osborne CK, for the Southwest Oncology Group: Megesterol acetate (MA) and aminoglutethimide/hydrocortisone (AG) in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc ASCO 10: 43, 1991
5. Nemoto T, Rosner D, Patel JK, Dao TL: Aminogluthethimide in patients with metastatic breast cancer. Cancer 63: 1673–1675, 1989